Prophylaxsis against recurrance of hepatitis B virus after liver transplantation
10.3760/cma.j.issn.1003-9279.2008.05.016
- VernacularTitle:肝移植术后乙型肝炎复发的预防
- Author:
Ju-Shan WU
1
;
Shi-Chun LU
;
Meng-Long WANG
;
Ren-Pin XIA
;
Qing-Liang GUO
;
Da-Ming GAO
;
Yi ZHANG
;
Yuan LIU
;
Ning LI
Author Information
1. 首都医科大学附属北京佑安医院
- Keywords:
Liver transplantation;
Hepatitis B virus;
Immunoglobulin;
Recurrence
- From:
Chinese Journal of Experimental and Clinical Virology
2008;22(5):367-369
- CountryChina
- Language:Chinese
-
Abstract:
Objective To summarize the clinical data in preventing HBV recurrence after liver transplantation and explore a optimal individual protocol in prophylaxis of HBV recurrence. Methods We retrospected outcomes in 195 recipients who underwent a liver transplantation for HBV-related liver disease between June 2004 and July 2008. According to the anti-virus protocol these recipients are divided into two groups as following: group A received a protocol of combination treatment of lamivudine with HBIG, and group B with combination treatment of adefovir with HBIG. With mean follow-up of 23.7 months, HBV recurrent rate was observed in overall and each group separately. Results A total of 195 liver transplant recipients were identified that met the study criteria. At the sixth and eleventh month after operation, HBV recurrence appeared in 2 recipients, each in two groups, which were due to LAM cessation and HBV mutation respectively. Recurrent rate was 0.6% in group A, 3.7% in group B and 1% in total. There was no significant difference in HBV recurrent rate between group A and B. Conclusion Lamivudine combined with HBIg should be considered as a reliable method in preventing HBV recurrence after liver transplantation. Better outcomes can be achieved by individual anti-virus protocol and HBIg administration according to HBV stares in recipient.
